Lilly and Novo Nordisk Clash in Weight-Loss Drug Market Showdown
The European Association for the Study of Diabetes (EASD) annual meeting in Milan has become a platform for Eli Lilly and Novo Nordisk to showcase their latest clinical evidence in the weight-loss drug market. Both pharmaceutical giants presented new data, with Eli Lilly revealing that its triple-G drug retatrutide achieved 34.9% body weight loss among patients on the highest dose. Novo Nordisk countered this by presenting real-world data suggesting Ozempic is associated with a 6% lower risk of major cardiovascular events compared to Lilly's Mounjaro.
The competitive intensity in the diabetes and weight-loss drug market is rising, with both companies vying for a larger share of the projected $100 billion market by 2030. Eli Lilly's retatrutide has garnered attention for its potential best-in-class efficacy, while Novo Nordisk defends its first-mover advantage through its oral Wegovy launch and pipeline expansion.
Other prominent pharmaceutical and biotech companies are also shaping the competitive landscape, including Pfizer, Amgen, and Regeneron Pharmaceuticals. These companies are developing their own weight-loss drugs, with some offering combination approaches targeting muscle preservation alongside fat loss.